
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+8
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer. Read more about Immatics on our homepage: https://immatics.com/ Find us also on: Twitter: https://twitter.com/immatics Instagram: https://www.instagram.com/immatics/...
Discovery of hla-restricted tumor-associated peptides as cancer targets,biomarkers,immunomonitoring,peptidomics & mass spectrometry,standardized pbmc collection,bioinformatics,immunology,tcr discovery,bispecific development,tcr-based immunotherapies,adoptive cell therapy,tcr bispecifics,and cancer
Immatics operates in the Biotechnology research industry.
Immatics's revenue is 101m - 500m
Immatics has 501 - 1000 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.